PMID- 30568653
OWN - NLM
STAT- MEDLINE
DCOM- 20191002
LR  - 20200309
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 9
DP  - 2018
TI  - Combination Strategies to Optimize Efficacy of Dendritic Cell-Based 
      Immunotherapy.
PG  - 2759
LID - 10.3389/fimmu.2018.02759 [doi]
LID - 2759
AB  - Dendritic cells (DCs) are antigen-presenting cells (APCs) that are essential for 
      the activation of immune responses. In various malignancies, these 
      immunostimulatory properties are exploited by DC-therapy, aiming at the induction 
      of effective anti-tumor immunity by vaccination with ex vivo antigen-loaded DCs. 
      Depending on the type of DC-therapy used, long-term clinical efficacy upon 
      DC-therapy remains restricted to a proportion of patients, likely due to lack of 
      immunogenicity of tumor cells, presence of a stromal compartment, and the 
      suppressive tumor microenvironment (TME), thereby leading to the development of 
      resistance. In order to circumvent tumor-induced suppressive mechanisms and 
      unleash the full potential of DC-therapy, considerable efforts have been made to 
      combine DC-therapy with chemotherapy, radiotherapy or with checkpoint inhibitors. 
      These combination strategies could enhance tumor immunogenicity, stimulate 
      endogenous DCs following immunogenic cell death, improve infiltration of 
      cytotoxic T lymphocytes (CTLs) or specifically deplete immunosuppressive cells in 
      the TME, such as regulatory T-cells and myeloid-derived suppressor cells. In this 
      review, different strategies of combining DC-therapy with immunomodulatory 
      treatments will be discussed. These strategies and insights will improve and 
      guide DC-based combination immunotherapies with the aim of further improving 
      patient prognosis and care.
FAU - van Gulijk, Mandy
AU  - van Gulijk M
AD  - Department of Pulmonary Medicine, Erasmus MC, Rotterdam, Netherlands.
AD  - Erasmus Cancer Institute, Erasmus MC, Rotterdam, Netherlands.
FAU - Dammeijer, Floris
AU  - Dammeijer F
AD  - Department of Pulmonary Medicine, Erasmus MC, Rotterdam, Netherlands.
AD  - Erasmus Cancer Institute, Erasmus MC, Rotterdam, Netherlands.
FAU - Aerts, Joachim G J V
AU  - Aerts JGJV
AD  - Department of Pulmonary Medicine, Erasmus MC, Rotterdam, Netherlands.
AD  - Erasmus Cancer Institute, Erasmus MC, Rotterdam, Netherlands.
FAU - Vroman, Heleen
AU  - Vroman H
AD  - Department of Pulmonary Medicine, Erasmus MC, Rotterdam, Netherlands.
AD  - Erasmus Cancer Institute, Erasmus MC, Rotterdam, Netherlands.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20181205
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Antigens, Neoplasm)
SB  - IM
MH  - Animals
MH  - Antigens, Neoplasm/immunology
MH  - Cell Death/immunology
MH  - Combined Modality Therapy/methods
MH  - Dendritic Cells/*immunology/pathology
MH  - Humans
MH  - Immunization/*methods
MH  - Myeloid-Derived Suppressor Cells/immunology/pathology
MH  - Neoplasms/immunology/pathology/*therapy
MH  - T-Lymphocytes, Cytotoxic/immunology/pathology
MH  - T-Lymphocytes, Regulatory/immunology/pathology
MH  - Tumor Microenvironment/immunology
PMC - PMC6289976
OTO - NOTNLM
OT  - DC-therapy
OT  - chemotherapy
OT  - combination therapy
OT  - immune checkpoint inhibitors
OT  - radiotherapy
EDAT- 2018/12/21 06:00
MHDA- 2019/10/03 06:00
PMCR- 2018/01/01
CRDT- 2018/12/21 06:00
PHST- 2018/08/31 00:00 [received]
PHST- 2018/11/09 00:00 [accepted]
PHST- 2018/12/21 06:00 [entrez]
PHST- 2018/12/21 06:00 [pubmed]
PHST- 2019/10/03 06:00 [medline]
PHST- 2018/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2018.02759 [doi]
PST - epublish
SO  - Front Immunol. 2018 Dec 5;9:2759. doi: 10.3389/fimmu.2018.02759. eCollection 
      2018.